Amgen

Amgen

Biotech company creating biologic medicines

Clean Utilities Engineer

Full-TimeUpdated on 9/30/2026Deadline 10/5/26
$88.3k - $119.4k/yr

+ Annual bonus + Stock-based long-term incentives

Senior, Expert
Bachelor's, Master's, Associate's
Holly Springs, NC, USA
In Person

About the job

Requirements
  • A high school diploma or GED and 8 years of engineering or maintenance experience, or an associate’s degree and 6 years of engineering or maintenance experience, or a bachelor’s degree and 2 years of engineering or maintenance experience, or a master’s degree.
  • Experience with equipment and facility control system operation, logic, and troubleshooting.
  • Experience working in a regulated environment such as current Good Manufacturing Practice, Occupational Safety and Health Administration, or Environmental Protection Agency environments, with familiarity with Good Manufacturing Practice quality systems and processes including change control, non-conformances, corrective and preventive actions, and qualification/validation.
  • Experience applying engineering principles to system modifications, new process introductions, and capital projects.
  • Understanding of capital project execution in a Good Manufacturing Practice biopharmaceutical production facility, including procurement, construction, startup, and validation.
  • Understanding of safety requirements in a Good Manufacturing Practice biopharmaceutical production facility.
  • Ability to support 24/7 operations with occasional after-hours engineering coverage.
Responsibilities
  • Provide system ownership for utility systems and equipment supporting site operations.
  • Provide engineering support for the design, construction, startup, commissioning, and qualification of new or modified systems.
  • Identify, support, and lead engineering-based improvements or upgrades for small- to medium-scope equipment or facility systems, including developing a business case when required.
  • Develop equipment and instrument maintenance programs, ensure spare-part availability, and coordinate maintenance execution.
  • Ensure systems are installed and operating safely and comply with applicable environmental health and safety practices, rules, and regulations.
  • Ensure commissioning and qualification of systems are completed in alignment with Good Manufacturing Practice requirements and interact with regulatory inspectors as necessary.
  • Apply basic engineering principles and practices to daily operation, maintenance, and troubleshooting of plant systems.
  • Monitor systems for performance risks and implement risk-reduction strategies.
  • Provide troubleshooting support to reduce production downtime, including leading or supporting technical root-cause analysis and corrective/preventive action implementation.
  • Support new product and technology introductions through engineering assessments, equipment modifications, and engineering runs.
  • Advance condition-based and predictive maintenance practices using advanced data analytics where applicable.
  • Own investigations of abnormal conditions through deviation and business processes.
  • Develop, coordinate, analyze, and present results for operational issues and engineering projects.
  • Provide technical support to commercial and clinical manufacturing, particularly for process control and process equipment.
  • Work with manufacturing, process engineering, process development, utility operations, maintenance, quality assurance, and validation groups to implement operational improvements.
  • Communicate with the supervisor and support staff by highlighting issues and proposing solutions.
  • Provide technical support and issue resolution through rotational 24/7 on-call coverage for utility systems.
  • Lead or collaborate with teams on the design, development, and selection of new systems, instruments, calibration capabilities, and consumable components.
  • Evaluate current and potential supplier capabilities and assess technologies that may provide cost savings, throughput improvements, or other capabilities to manufacturing.
Desired Qualifications
  • A bachelor’s degree in chemical engineering or mechanical engineering.
  • At least 2 years of relevant work experience, including at least 2 years in a biopharmaceutical operations or manufacturing environment.
  • Direct knowledge of design and troubleshooting for Good Manufacturing Practice biopharmaceutical production-facility utility systems, including pharmaceutical water, clean steam, clean air generation and distribution, and clean-in-place systems, as well as chilled-water chillers, cooling towers, steam boilers, and air compressors.
  • Strong leadership, technical writing, communication, and presentation skills, with the ability to work with minimal direction.
  • Interpersonal and facilitation skills and the ability to work in a collaborative, team-based environment.
  • Ability to apply analytical skills to evaluate and interpret complex problems using multiple information sources.
  • Ability to function within cross-functional teams.
  • Ability to work independently, manage multiple tasks in project environments, and support team-based decision-making.
  • Schedule flexibility to support 24/7 operations and occasional after-hours engineering coverage.

About the company

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 9% to $10.1 billion, with six growth drugs up 26%.
  • Repatha sales jumped 37% in Q2 2026, and Medicare-access expansion broadens prescriptions.
  • MariTide entered nine Phase 3 studies in 2026, targeting obesity, diabetes, sleep apnea, and cardiovascular disease.

What critics are saying

  • Bristol Myers and Ono sued Amgen on Sept. 15, 2026, over Opdivo biosimilar patents.
  • Britain suspended Tavneos for new patients in September 2026 after calling supporting data unreliable.
  • Prolia and XGEVA biosimilar pressure already cut Q2 2026 sales 33%, and MariTide is unproven.

What makes Amgen unique

  • Amgen’s Aug. 2026 pipeline spans Repatha, IMDELLTRA, MariTide, and olpasiran simultaneously.
  • Repatha holds primary- and secondary-prevention outcomes data, uncommon among PCSK9 competitors.
  • IMDELLTRA became an August 2026 growth engine, reaching $288 million quarterly sales.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.

Yahoo Finance
Sep 11th, 2026
Revolution Medicines' first pancreatic cancer therapy approval challenges Amgen's biotech dominance

Revolution Medicines received FDA approval for daraxonrasib, the first targeted therapy for metastatic pancreatic cancer, after clinical data showed it reduced death risk by more than half. The company is clinical-stage with no current revenue and posted a $1.1 billion net loss in FY 2025. Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. Free cash flow reached $8.1 billion. The company carries a debt-to-equity ratio of 6.3x. Revolution Medicines maintains a 0.1x debt-to-equity ratio and 9.5x current ratio but recorded negative free cash flow of $913.7 million. The company's pipeline targets RAS-driven tumours including lung cancer. A partnership with Royalty Pharma provides funding for development. Both companies face distinct risks: Amgen confronts pricing pressures and biosimilar competition, whilst Revolution Medicines carries clinical trial failure risks and competes against larger pharmaceutical firms.

Yahoo Finance
Sep 11th, 2026
Amgen vs CRISPR Therapeutics: Which healthcare stock offers better value in 2026?

Amgen reported revenue of $36.7 billion in FY 2025, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech giant maintains a debt-to-equity ratio of 6.3x and generated $8.1 billion in free cash flow. CRISPR Therapeutics, meanwhile, saw revenue fall 90% to $3.5 million in FY 2025, posting a net loss of $581.6 million. The gene-editing firm burns $345.9 million in cash but holds a strong current ratio of 13.3x. Its CASGEVY therapy for sickle cell disease has gained approval in the US, UK, and EU, with Vertex handling commercialisation under a 60-40 revenue split. Amgen faces pricing pressure from the Inflation Reduction Act and biosimilar competition. CRISPR Therapeutics carries clinical execution risk and ongoing intellectual property disputes.

Yahoo Finance
Sep 11th, 2026
Amgen and AstraZeneca lung cancer drug combo meets survival goal in phase III study

Amgen and AstraZeneca announced positive results from the phase III DeLLphi-305 study evaluating Amgen's Imdelltra (tarlatamab) combined with AstraZeneca's Imfinzi (durvalumab) as first-line maintenance treatment for extensive-stage small-cell lung cancer (ES-SCLC). The study met its primary endpoint of overall survival and key secondary endpoint of progression-free survival, with no new safety concerns identified. ES-SCLC affects approximately 195,000 people globally. If approved, the combination would compete with Jazz Pharmaceuticals' Zepzelca plus Roche's Tecentriq, which received FDA approval in October 2025. Imdelltra, approved in 2024 for ES-SCLC progression after platinum-based chemotherapy, generated $546 million in global sales during the first half of 2026, up from $215 million in the prior-year period.

Yahoo Finance
Sep 10th, 2026
Amgen vs. Moderna: Which healthcare stock is a better buy in 2026?

Amgen reported FY 2025 revenue of $36.7 billion, up 9.9% year-over-year, with net income of $7.7 billion and a 21% net margin. The biotech serves 17 million patients globally with treatments for heart disease, obesity, and cancer. However, three distributors—McKesson, Cencora, and Cardinal Health—accounted for 77% of gross revenues, creating concentration risk. The company's debt-to-equity ratio stood at 6.3x. Moderna posted FY 2025 revenue of $1.9 billion, down 39.2% as pandemic-related vaccine demand declined. The mRNA specialist reported a net loss of $2.8 billion, resulting in a negative 145.2% net margin due to high research and development costs. The company is pivoting its mRNA platform toward infectious diseases, cancer, and rare conditions whilst expanding through partnerships like its collaboration with Merck.